For the year ending 2025-12-31, ENSC had $808,277 increase in cash & cash equivalents over the period. -$7,929,935 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -10,176,187 |
| Accrued interest | 12,393 |
| Change in fair value of liability classified warrants | 10,096 |
| Consultant compensation | 668,682 |
| Stock-based compensation | 177,086 |
| Depreciation expense | 6,533 |
| Unbilled receivable | 296,230 |
| Prepaid expenses and other assets | 438,565 |
| Accounts payable | 1,815,658 |
| Accrued expenses and other liabilities | 434,434 |
| Net cash used in operating activities | -7,806,292 |
| Investment in property and equipment | 123,643 |
| Net cash flows used in investing activities | -123,643 |
| Proceeds from public offerings | 1,100,007 |
| Proceeds from warrant exercises | 2,572,067 |
| Proceeds from warrant inducement, net of issuance costs | 2,200,012 |
| Proceeds from issuance of series b preferred stock | 3,975,000 |
| Transaction costs associated with public offering and warrant inducements | 501,214 |
| Transaction costs associated with series b preferred stock issuance | 391,376 |
| Repayment of financed insurance premiums | 216,284 |
| Net cash provided by financing activities | 8,738,212 |
| Increase in cash and cash equivalents | 808,277 |
| Cash and cash equivalents beginning of period | 3,502,077 |
| Cash and cash equivalents end of period | 4,310,354 |
Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc. (ENSC)